Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.70 USD
−182.63 M USD
610.78 M USD
110.42 M
About 10x Genomics, Inc.
Sector
Industry
CEO
Serge Saxonov
Website
Headquarters
Pleasanton
Founded
2012
ISIN
US88025U1097
FIGI
BBG007WX14X0
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BOATS exchange 10x Genomics, Inc. stocks are traded under the ticker TXG.
We've gathered analysts' opinions on 10x Genomics, Inc. future price: according to them, TXG price has a max estimate of 17.00 USD and a min estimate of 12.00 USD. Watch TXG chart and read a more detailed 10x Genomics, Inc. stock forecast: see what analysts think of 10x Genomics, Inc. and suggest that you do with its stocks.
Yes, you can track 10x Genomics, Inc. financials in yearly and quarterly reports right on TradingView.
10x Genomics, Inc. is going to release the next earnings report on Oct 29, 2025. Keep track of upcoming events with our Earnings Calendar.
TXG earnings for the last quarter are 0.28 USD per share, whereas the estimation was −0.37 USD resulting in a 175.72% surprise. The estimated earnings for the next quarter are −0.29 USD per share. See more details about 10x Genomics, Inc. earnings.
10x Genomics, Inc. revenue for the last quarter amounts to 172.91 M USD, despite the estimated figure of 139.44 M USD. In the next quarter, revenue is expected to reach 142.64 M USD.
TXG net income for the last quarter is 34.54 M USD, while the quarter before that showed −34.36 M USD of net income which accounts for 200.52% change. Track more 10x Genomics, Inc. financial stats to get the full picture.
No, TXG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 10, 2025, the company has 1.31 K employees. See our rating of the largest employees — is 10x Genomics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. 10x Genomics, Inc. EBITDA is −109.29 M USD, and current EBITDA margin is −24.31%. See more stats in 10x Genomics, Inc. financial statements.
Like other stocks, TXG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade 10x Genomics, Inc. stock right from TradingView charts — choose your broker and connect to your account.